ADC Therapeutics SA (ADCT) stock
ADCTNYSEPharmaceutical PreparationsFiscal year ends December 31
$1.37+0.02 (+1.48%)
Close on Nov 18, 2026Market cap $174.91MP/E –Yield –
ADC Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
ADC Therapeutics's free cash flow for the twelve months ending Sep 30, 2026 was -$100.55M. For fiscal 2025 it was -$141.44M. The highest annual figure on record is -$121.90M in fiscal 2023.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$141.44M | – |
| FY2024 | Dec 31, 2024 | -$124.70M | – |
| FY2023 | Dec 31, 2023 | -$121.90M | – |
| FY2022 | Dec 31, 2022 | -$139.00M | – |
| FY2021 | Dec 31, 2021 | -$236.81M | – |
| FY2020 | Dec 31, 2020 | -$169.53M | – |
| FY2019 | Dec 31, 2019 | -$121.94M | – |
| FY2018 | Dec 31, 2018 | -$122.31M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$27.88M | – |
| Q2 FY2026 | Jun 30, 2026 | -$11.81M | – |
| Q1 FY2026 | Mar 31, 2026 | -$29.74M | – |
| Q4 FY2025 | Dec 31, 2025 | -$31.12M | – |
| Q3 FY2025 | Sep 30, 2025 | -$29.63M | – |
| Q2 FY2025 | Jun 30, 2025 | -$24.09M | – |
| Q1 FY2025 | Mar 31, 2025 | -$56.60M | – |
| Q4 FY2024 | Dec 31, 2024 | -$21.94M | – |
| Q3 FY2024 | Sep 30, 2024 | -$25.26M | – |
| Q2 FY2024 | Jun 30, 2024 | -$32.88M | – |
| Q1 FY2024 | Mar 31, 2024 | -$44.63M | – |
| Q4 FY2023 | Dec 31, 2023 | -$31.96M | – |
| Q3 FY2023 | Sep 30, 2023 | -$37.33M | -1965.8% |
| Q2 FY2023 | Jun 30, 2023 | -$36.20M | – |
| Q1 FY2023 | Mar 31, 2023 | -$16.41M | – |
| Q4 FY2022 | Dec 31, 2022 | -$53.83M | – |
| Q3 FY2022 | Sep 30, 2022 | $2.00M | – |
| Q2 FY2022 | Jun 30, 2022 | -$53.06M | – |
| Q1 FY2022 | Mar 31, 2022 | -$34.11M | – |
| Q4 FY2021 | Dec 31, 2021 | -$62.05M | – |
| Q3 FY2021 | Sep 30, 2021 | -$59.99M | – |
| Q2 FY2021 | Jun 30, 2021 | -$58.96M | – |
| Q1 FY2021 | Mar 31, 2021 | -$55.81M | – |
| Q4 FY2020 | Dec 31, 2020 | -$51.87M | – |
| Q3 FY2020 | Sep 30, 2020 | -$44.69M | – |
| Q2 FY2020 | Jun 30, 2020 | -$40.77M | – |
| Q1 FY2020 | Mar 31, 2020 | -$32.20M | – |
See a number that looks wrong?